Cargando…

Novel therapeutic strategies in the treatment of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not...

Descripción completa

Detalles Bibliográficos
Autores principales: Oualla, Karima, El-Zawahry, Heba M., Arun, Banu, Reuben, James M., Woodward, Wendy A., Gamal El-Din, Heba, Lim, Bora, Mellas, Nawfel, Ueno, Naoto T., Fouad, Tamer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502951/
https://www.ncbi.nlm.nih.gov/pubmed/28717401
http://dx.doi.org/10.1177/1758834017711380
_version_ 1783249012559708160
author Oualla, Karima
El-Zawahry, Heba M.
Arun, Banu
Reuben, James M.
Woodward, Wendy A.
Gamal El-Din, Heba
Lim, Bora
Mellas, Nawfel
Ueno, Naoto T.
Fouad, Tamer M.
author_facet Oualla, Karima
El-Zawahry, Heba M.
Arun, Banu
Reuben, James M.
Woodward, Wendy A.
Gamal El-Din, Heba
Lim, Bora
Mellas, Nawfel
Ueno, Naoto T.
Fouad, Tamer M.
author_sort Oualla, Karima
collection PubMed
description Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.
format Online
Article
Text
id pubmed-5502951
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55029512017-07-17 Novel therapeutic strategies in the treatment of triple-negative breast cancer Oualla, Karima El-Zawahry, Heba M. Arun, Banu Reuben, James M. Woodward, Wendy A. Gamal El-Din, Heba Lim, Bora Mellas, Nawfel Ueno, Naoto T. Fouad, Tamer M. Ther Adv Med Oncol Reviews Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC. SAGE Publications 2017-06-13 2017-07 /pmc/articles/PMC5502951/ /pubmed/28717401 http://dx.doi.org/10.1177/1758834017711380 Text en © The Author(s), 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Reviews
Oualla, Karima
El-Zawahry, Heba M.
Arun, Banu
Reuben, James M.
Woodward, Wendy A.
Gamal El-Din, Heba
Lim, Bora
Mellas, Nawfel
Ueno, Naoto T.
Fouad, Tamer M.
Novel therapeutic strategies in the treatment of triple-negative breast cancer
title Novel therapeutic strategies in the treatment of triple-negative breast cancer
title_full Novel therapeutic strategies in the treatment of triple-negative breast cancer
title_fullStr Novel therapeutic strategies in the treatment of triple-negative breast cancer
title_full_unstemmed Novel therapeutic strategies in the treatment of triple-negative breast cancer
title_short Novel therapeutic strategies in the treatment of triple-negative breast cancer
title_sort novel therapeutic strategies in the treatment of triple-negative breast cancer
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502951/
https://www.ncbi.nlm.nih.gov/pubmed/28717401
http://dx.doi.org/10.1177/1758834017711380
work_keys_str_mv AT ouallakarima noveltherapeuticstrategiesinthetreatmentoftriplenegativebreastcancer
AT elzawahryhebam noveltherapeuticstrategiesinthetreatmentoftriplenegativebreastcancer
AT arunbanu noveltherapeuticstrategiesinthetreatmentoftriplenegativebreastcancer
AT reubenjamesm noveltherapeuticstrategiesinthetreatmentoftriplenegativebreastcancer
AT woodwardwendya noveltherapeuticstrategiesinthetreatmentoftriplenegativebreastcancer
AT gamaleldinheba noveltherapeuticstrategiesinthetreatmentoftriplenegativebreastcancer
AT limbora noveltherapeuticstrategiesinthetreatmentoftriplenegativebreastcancer
AT mellasnawfel noveltherapeuticstrategiesinthetreatmentoftriplenegativebreastcancer
AT uenonaotot noveltherapeuticstrategiesinthetreatmentoftriplenegativebreastcancer
AT fouadtamerm noveltherapeuticstrategiesinthetreatmentoftriplenegativebreastcancer